Description
Human CellExp™ CD30 /TNFRSF8, human recombinant is available at Gentaur for Next week delivery.
May play a role in the regulation of cellular growth and transformation of activated lymphoblasts
Biomolecule/Target: CD30 /TNFRSF8
Alternates names: TNFRSF8, CD30, D1S166E, Ki-1
Synonyms: TNFRSF8, CD30, D1S166E, Ki-1
Background Information: Human CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.
Reconstitution Instructions: Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.
NCBI Gene Symbol: TNFRSF8
Gene ID: 943
NCBI Accession: P28908
Additional Information
Size: |
50 μg |
Country of Manufacturing Origin: |
USA |
Country of Animal Origin: |
USA |
Gene Source: |
Human |
Recombinant: |
Yes |
Source: |
HEK293 cells |
Purity by SDS-PAGE: |
≥95% |
Assay: |
SDS-PAGE |
Purity: |
N/A |
Assay 2: |
N/A |
Endotoxin Level: |
<1 EU/μg by LAL method |
Activity (Specifications/test method): |
N/A |
Biological activity: |
Measured by its ability to block CD30 Ligand-induced IL-6 secretion by HDLM human Hodgkin’s lymphoma cells. The ED50 for this effect is typically 0.5 - 2.5 µg/ml in the presence of 50 ng/ml of Recombinant Human CD30 Ligand. |
Results: |
Measured by its ability to block CD30 Ligand-induced IL-6 secretion by HDLM human Hodgkin’s lymphoma cells. The ED50 for this effect is typically 0.5 - 2.5 µg/ml in the presence of 50 ng/ml of Recombinant Human CD30 Ligand. |
Molecular Weight: |
This protein is fused with 6×His tag at the C-terminus, has a calculated MW of 39.3 kDa. The predicted N-terminus is Phe 19. DTT-reduced Protein migrates as 75-90 kDa due to glycosylation. |
Storage Temperature: |
-20°C |
Shelf Life: |
12 months |
Concentration: |
N/A |
Appearance: |
Lyophilized |
Handling: |
Centrifuge the vial prior to opening. |